Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empliciti with ASCT and Revlimid in Multiple Myeloma
NCT02655458Phase 1Completed
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of elotuzumab in multiple myeloma (MM). Primary endpoint: Incidence of completion of treatment at 24 months. Started Jan 2016; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02655458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655458.